Investor Presentaiton

в 8 Jeuveau: A Neurotoxin by Design State-of-the-Art Manufacturing with Patented Hi-Pure™ Technology Jeuveau prabotulinumtoxinA-xvfs injection 900 kDa prabotulinumtoxinA + Purification method: Crystallization Finishing method: Vacuum dried 0.5 mg Human Serum Albumin + 0.9 mg salt R Jeuveau Global Clinical Program: >2,100 Patients Across Five Clinical Trials U.S. Phase III: JeuveauⓇ vs Placebo Two identical Phase III safety and efficacy studies (EV-001 & EV-002) Multicenter, randomized, double-blind, placebo controlled, single dose Placebo-controlled, superiority design EV-001 n = 330 EV-002 n = 324 Head-to-head EU/Canada Phase III trial: JeuveauⓇ vs Botox EU / Canada Phase III safety and efficacy (EVB-003) Multicenter, randomized, double-blind, placebo & active controlled, single dose Active control, non-inferiority design versus Botox n = 540 Ⓡ Jeuveau Safety Studies U.S. Phase II Long-Term Safety Studies (EV-004 & EV-006) One-year multicenter, non-randomized, open label, multiple dose EV-004 n = 352 EV-006 n = 570 13

View entire presentation